CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial - The Lancet
Daunorubicin - Wikipedia
Primary AML cells and cell lines resistant to cytarabine, daunorubicin... | Download Scientific Diagram
Effect of Ara-C, daunorubicin, mitoxantrone and etoposide on the... | Download Scientific Diagram
Contrastive Studies of Cytarabine/Daunorubicin Dual-Loaded Liposomes Prepared by pH Gradient and Cu2+ Gradient Method | SpringerLink
Binding of Released Bim to Mcl-1 is a Mechanism of Intrinsic Resistance to ABT-199 which can be Overcome by Combination with Daunorubicin or Cytarabine in AML Cells. - Abstract - Europe PMC
Determination of free and encapsulated cytarabine and daunorubicin in rat plasma after intravenous administration of liposomal formulation using ultra-high performance liquid chromatography tandem mass spectrometry - ScienceDirect
7+3 (daunorubicin) for AML | ChemoExperts
Panobinostat Enhances Cytarabine and Daunorubicin Sensitivities in AML Cells through Suppressing the Expression of BRCA1, CHK1, and Rad51 | PLOS ONE
Rethinking the Treatment of Older Adults With Acute Myeloid Leukemia - ppt download
Acute myeloid leukemia—Major progress over four decades and glimpses into the future - Kantarjian - 2016 - American Journal of Hematology - Wiley Online Library
A comparison of clofarabine with ara-C, each in combination with daunorubicin as induction treatment in older patients with acute myeloid leukaemia | Leukemia
Radotinib enhances cytarabine (Ara-C)-induced acute myeloid leukemia cell death | BMC Cancer | Full Text
Venetoclax and alvocidib are both cytotoxic to acute myeloid leukemia cells resistant to cytarabine and clofarabine | BMC Cancer | Full Text
2043-Induction 7-3 (cytarabine and DAUNOrubicin) | eviQ
Venetoclax plus 3 + 7 daunorubicin and cytarabine chemotherapy as first-line treatment for adults with acute myeloid leukaemia: a multicentre, single-arm, phase 2 trial - The Lancet Haematology
Fernand Bteich on Twitter: "13/ Typical induction regimen is 7+3. Total is 7 days with 3 days of overlap. 7 days of cytarabine infusion. 3 days of anthracycline infusion (daunorubicin or idarubicin).
A Review of Liposomal Daunorubicin in the Treatment of Acute Leukemia - touchONCOLOGY
Addition of cladribine to daunorubicin and cytarabine increases complete remission rate after a single course of induction treatment in acute myeloid leukemia. Multicenter, phase III study | Leukemia
Clofarabine, high-dose cytarabine and liposomal daunorubicin in pediatric relapsed/refractory acute myeloid leukemia: a phase IB study | Haematologica
Rx Item-Vyxeos- (Daunorubicin And Cytarabine) Liposome Injection, Powder, By Jaz
Response and Toxicity to Cytarabine Therapy in Leukemia and Lymphoma: From Dose Puzzle to Pharmacogenomic Biomarkers
Cancer Management Chapter 29: Acute leukemias
